Methylation Array Profiling as a New Clinical Diagnostic Test

甲基化阵列分析作为一种新的临床诊断测试

• 批准号: 10262814
• 负责人: Svetlana Pack
• 金额: $ 38.93万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262814
• 关键词: Accreditation; CCR; Central Nervous System Neoplasms; Certification; Chromosomes; Clinical; Clinical Research; Clinical Services; Collaborations; Communities; Copy Number Polymorphism; Data; Diagnosis; Diagnostic tests; Epigenetic Process; Individual; Methylation; Molecular Profiling; Morphology; Pathology; Reporting; Research Project Grants; Work; base; cancer subtypes; clinical diagnostics; genome-wide; molecular diagnostics; neuro-oncology; novel; personalized diagnostics; research clinical testing; therapy outcome; transcriptome sequencing; tumor

Another milestone in Chromosome Pathology Section is the introduction of the Methylation Array analysis as a novel clinical test (under CLIA certification, CAP accreditation) offered to the CCR and outside clinical community. Establishing a comprehensive tumor molecular profile would assist ultimately in diagnostic precision and overall would impact the treatment decision and the outcome of the therapy. Methylation array analysis based on Illumina platform has been introduced to become an important addition to existing molecular diagnostic menu. Methylation array-based clinical testing became live for analysis of the Central Nervous System (CNS) tumor analysis in March 2019 with over 800 clinical cases been officially reported or studied as part of clinical research projects. This work is being performed in collaboration with the Neuro-Oncology Branch, NCI.

染色体病理学部分的另一个里程碑是引入甲基化芯片分析作为一种新颖的临床测试（经过 CLIA 认证、CAP 认证），提供给 CCR 和外部临床界。建立全面的肿瘤分子谱将最终有助于提高诊断精度，并且总体上会影响治疗决策和治疗结果。基于Illumina平台的甲基化芯片分析已被引入，成为现有分子诊断菜单的重要补充。基于甲基化芯片的临床测试于 2019 年 3 月开始用于中枢神经系统 (CNS) 肿瘤分析，作为临床研究项目的一部分，正式报告或研究了 800 多个临床病例。这项工作是与 NCI 神经肿瘤科合作进行的。